RBC Capital Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $3

RBC Capital analyst Brian Abrahams maintains $Karyopharm Therapeutics(KPTI.US)$ with a buy rating, and maintains the target price at $3.According to TipRanks data, the analyst has a success rate of 49

moomoo NewsJun 10 07:31 ET · Ratings

Karyopharm Therapeutics(KPTI.US) Director Sells US$785.03K in Common Stock

$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 818.04K shares of common stock on Jun 5, 6, 7, 2024 at an average price of $0.9596 for a total value of $785.03K.Source: Announceme

moomoo NewsJun 7 20:00 ET

Karyopharm Therapeutics(KPTI.US) Director Sells US$880.69K in Common Stock

$Karyopharm Therapeutics(KPTI.US)$ Director PAKIANATHAN DEEPIKA sold 906.18K shares of common stock on May 31, Jun 3, 4, 2024 at an average price of $0.9719 for a total value of $880.69K.Source: Annou

moomoo NewsJun 4 19:31 ET

Barclays Remains a Buy on Karyopharm Therapeutics (KPTI)

TipRanksJun 3 05:39 ET

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEWTON, Mass., June 3, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company g

Karyopharm TherapeuticsJun 3 00:00 ET

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024

BenzingaJun 2 14:37 ET